The monitoring of chimerism has become a routine diagnostic instrument at centers performing allogeneic stem cell or bone marrow transplantation. Despite the widespread use of molecular techniques permitting the assessment and the surveillance of donor-and recipient-derived hemopoiesis, there have been no international efforts to standardize the technical approaches, and to provide a basis for the comparison of diagnostic results. We believe that in this rapidly growing field there is a need for standardization directed towards optimum diagnostic support for clinical decision making.
The Debate Round- Table has been opened in LEUKEMIA in 1999 (Vol 13; issue 12, pp 2059 -2086 . The most recent article within the Debate appeared in May 2004 (Vol 18, issue 5, pp 909-911). In this issue, LEUKEMIA presents a new contribution to the Debate illustrating some of the ideas, which we hope will stimulate further discussion of important aspects of chimerism analysis. The paper by Jiménez-Velasco et al presents an alternative technical approach to chimerism testing based on real-time PCR analysis of the so-called null alleles and indels. This approach appears to permit quantitative analysis of chimerism kinetics at a level of sensitivity higher than many of the currently used techniques, thus facilitating earlier assessment of impending relapse in patients transplanted for treatment for acute leukemia.
Based on the results of this debate and the current state of the art, we would like to establish generally accepted standards for chimerism testing in the light of the possible therapeutic implications. In the clinically oriented part of the debate, we would like to discuss the optimum timing of chimerism analysis, and the therapy options inferable from molecular monitoring in different transplant settings.
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Contributions to the Debate should be labeled 'Round Table  on Chimerism Testing', and sent to the LEUKEMIA office in Paris, which will transmit the manuscripts to the Guest Editor of the Debate (T Lion). There is no limitation to the number of participants in the Debate. The contributions can be short notes of up to 2500 words with a few references, regular papers or editorials. Leukemia (2005) 
